 |
Justin Petrone is the editor of GenomeWeb's BioArray News and covers the microarray and biochip sector of the genomics market. E-mail Justin Petrone or follow his GenomeWeb Twitter account at @BioArrayNews. |
Luminex Expects 2013 FDA Clearance for Gastro Pathogen Panel as Q3 Revenues Rise 10 Percent
October 30, 2012
Luminex Expects 2013 FDA Clearance for Gastro Pathogen Panel as Q3 Revenues Rise 10 Percent
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Luminex's 2013 Priorities Include GPP, NeoPlex Adoption, MagPix Placements, Project Aries
February 5, 2013 / BioArray News - UPDATE: Luminex Gains FDA Clearance for Gastro Test; Expects Clearance for Newborn Test in H2
January 15, 2013 / BioArray News - Despite Continued Genotyping Growth, Weak Expression Sales Force Affymetrix to Suspend Guidance
May 7, 2013 / BioArray News - Luminex, Posting Q1 Revenue Growth, Provides Updates on Gastro Pathogen, NeoPlex Assays
April 30, 2013 / BioArray News - Luminex to Target Smaller Clinical Labs with FDA-Cleared MagPix System, Gastro Pathogen Panel
April 16, 2013 / BioArray News